Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 18;3(2):e00548-17.
doi: 10.1128/mSphere.00548-17. Print 2018 Apr 25.

Molecular Preadaptation to Antimony Resistance in Leishmania donovani on the Indian Subcontinent

Affiliations

Molecular Preadaptation to Antimony Resistance in Leishmania donovani on the Indian Subcontinent

F Dumetz et al. mSphere. .

Abstract

Antimonials (Sb) were used for decades for chemotherapy of visceral leishmaniasis (VL). Now abandoned in the Indian subcontinent (ISC) because of Leishmania donovani resistance, this drug offers a unique model for understanding drug resistance dynamics. In a previous phylogenomic study, we found two distinct populations of L. donovani: the core group (CG) in the Gangetic plains and ISC1 in the Nepalese highlands. Sb resistance was only encountered within the CG, and a series of potential markers were identified. Here, we analyzed the development of resistance to trivalent antimonials (SbIII) upon experimental selection in ISC1 and CG strains. We observed that (i) baseline SbIII susceptibility of parasites was higher in ISC1 than in the CG, (ii) time to SbIII resistance was higher for ISC1 parasites than for CG strains, and (iii) untargeted genomic and metabolomic analyses revealed molecular changes along the selection process: these were more numerous in ISC1 than in the CG. Altogether these observations led to the hypothesis that CG parasites are preadapted to SbIII resistance. This hypothesis was experimentally confirmed by showing that only wild-type CG strains could survive a direct exposure to the maximal concentration of SbIII The main driver of this preadaptation was shown to be MRPA, a gene involved in SbIII sequestration and amplified in an intrachromosomal amplicon in all CG strains characterized so far. This amplicon emerged around 1850 in the CG, well before the implementation of antimonials for VL chemotherapy, and we discuss here several hypotheses of selective pressure that could have accompanied its emergence.IMPORTANCE The "antibiotic resistance crisis" is a major challenge for scientists and medical professionals. This steady rise in drug-resistant pathogens also extends to parasitic diseases, with antimony being the first anti-Leishmania drug that fell in the Indian subcontinent (ISC). Leishmaniasis is a major but neglected infectious disease with limited therapeutic options. Therefore, understanding how parasites became resistant to antimonials is of commanding importance. In this study, we experimentally characterized the dynamics of this resistance acquisition and show for the first time that some Leishmania populations of the ISC were preadapted to antimony resistance, likely driven by environmental factors or by drugs used in the 19th century.

Keywords: Leishmania; antimonials; drug resistance mechanisms; genomics; metabolomics.

PubMed Disclaimer

Figures

FIG 1
FIG 1
SbIII susceptibility of promastigotes from ISC1 and core group (CG) strains. The three ISC1 strains (red) and the seven strains of CG (blue) are representative of the overall genetic diversity previously described in reference . SbIII susceptibility for each strain was determined by three independent experiments using potassium antimony tartrate as an SbIII source. *, P < 0.05 by ANOVA.
FIG 2
FIG 2
Dynamics of SbIII resistance selection. (A and B) Flowchart of SbIII resistance selection for CG strains BPK282 and BPK275 (A) and ISC1 strain BPK026 (B). Boxes indicate the increasing SbIII concentrations (6 to 382 µM), and black lines are for the stepwise selection (SW) and blue lines for the flash selection (FS) of the different replicates (populations A to D). “5P” represents 5 in vitro passages. Red crosses show replicates that did not survive the selection pressure at a given drug concentration. Solid-line boxes represent samples analyzed at the genomic and metabolomics levels, and dashed-line boxes represent samples analyzed at the genomic level only. If no box is present, the samples were not analyzed. (C) Time to resistance in weeks for the 3 SbIII stepwise-selected (SW [black lines]) and flash-selected (FS [blue lines]) strains.
FIG 3
FIG 3
Genomic analysis of the selected SbIII-resistant strains. (A) Evolution of allele frequency over the SbIII resistance selection process of BPK026 for a fusaric acid resistance protein-like protein (LdBPK_120011000-H1104T) and the intraflagellar transport protein (LdBPK_210017400-Δ1699). (B and C) Heat map representing the karyotype dynamics across the SbIII resistance selection of BPK282 and BPK275. (D) High hierarchical representation of BPK026 karyotype evolution. Heat maps show median normalized read depths of chromosomes found within each cell population for each of the 36 chromosomes (y axis) and each sample (x axis), replicate populations called A, B, C, and D are shown for each selecting SbIII concentration (from 6 to 382 µM), and the samples “WT” framed in a black box represent the parental SbIII-sensitive population for each strain. The color key for panels B and C shows the normalized chromosome read depth (S). S ranges are as follows: monosomy, S < 1.5 (dark blue); disomy, 1.5 ≤ S < 2.5 (light blue); trisomy, 2.5 ≤ S < 3.5 (green); tetrasomy, 3.5 ≤ S < 4.5 (orange); pentasomy, 4.5 ≤ S < 5.5 (red). In panel D, the ranges are as follows: monosomy, S < 1.5 (dark blue); disomy, 1.5 ≤ S < 2.5 (blue); trisomy, 2.5 ≤ S < 3.5 (light blue); tetrasomy, 3.5 ≤ S < 4.5 (green); pentasomy, 4.5 ≤ S < 5.5 (yellow); hexasomic, 5.5 ≤ S < 6.5 (orange); heptasomic, 6.5 ≤ S < 7.5 (red). A black triangle in an upper right corner indicates a significant change in S value (>0.5, with a shift from one S range to another and a P value of ≤10−5) in comparison to the S value of the starting population (sample “0” framed in a black box). (E) The left panel shows the normalized read depth of chromosome 23 (trisomic) compared, as a control, to the normalized read depth of chromosome 27 (disomic) in the parental strain BPK026 (BPK026 WT), and the right panel shows the normalized read depth for these two chromosomes in BPK026 SbIII-R. (F) Normalized read depth of the fragment of chromosome 23 harboring the H locus. The left panel displays the parental strains (BPK026 WT, BPK275 WT, and BPK282 WT), while the right panel shows SbIII-R line B for the three isolates.
FIG 4
FIG 4
Importance of H and M loci for SbIII resistance. (A) Expression levels of genes of the M locus (above) and H locus (below) in parental lines (BPK026 WT, BPK282 WT, and BPK275 WT) and one respective SbIII-resistant population (BPK026 SbIII-R pop B, BPK282 SbIII-R pop B, and BPK275 SbIII-R pop B) were measured by qRT-PCR. Data were first normalized to the stable SAT gene and LdBPK_240021200 genes and then rescaled to the levels of BPK026 WT. Data are means ± standard deviation (SD) from two independent experiments. (B) SbIII susceptibility of the BPK026 WT and BPK026 WT transfected with the H or M locus or with the individual genes of these loci. Data are means from three independent experiments. *, P < 0.05 by ANOVA.
FIG 5
FIG 5
Metabolomics analysis of the selected SbIII-resistant strains. (A) Principal-component analysis based on 300 metabolites and including the initial parental strains (WT) BPK026 (green), BPK275 (red), and BPK282 (blue), the final populations resistant to 382 µM SbIII (BPK026 382B, BPK275 382B, -C, and -D, and BPK282 382B, -C, and -D) as well as BPK026 intermediates (12B and 24B, respectively, resistant to 12 and 24 µM SbIII). (B) Venn diagrams showing metabolites significantly different between strains. (C) High hierarchical representation of amino acid abundance in the different strains, including the parental strains (BPK026 WT, BPK282 WT, and BPK275 WT) and the selected populations resistant to 382 µM SbIII (BPK275 382B, -C, and -D, BPK026 382B, and BPK282 382B, -C, and -D).
FIG 6
FIG 6
Flash selection with 382 µM SbIII on ISC1 and CG strains. Shown are growth curves over 5 weeks of three ISC1 strains (red) and seven CG strains (blue) in the presence of 382 µM SbIII. Each point represents the average value of promastigote counts in three independent flasks.

References

    1. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. 2007. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5:873–882. doi:10.1038/nrmicro1748. - DOI - PubMed
    1. Séguin O, Descoteaux A. 2016. Leishmania, the phagosome, and host responses: the journey of a parasite. Cell Immunol 309:1–6. doi:10.1016/j.cellimm.2016.08.004. - DOI - PubMed
    1. Mookerjee Basu J, Mookerjee A, Sen P, Bhaumik S, Sen P, Banerjee S, Naskar K, Choudhuri SK, Saha B, Raha S, Roy S. 2006. Sodium-antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother 50:1788–1797. doi:10.1128/AAC.50.5.1788-1797.2006. - DOI - PMC - PubMed
    1. Hansen C, Hansen EW, Hansen HR, Gammelgaard B, Stürup S. 2011. Reduction of Sb(V) in a human macrophage cell line measured by HPLC-ICP-MS. Biol Trace Elem Res 144:234–243. doi:10.1007/s12011-011-9079-9. - DOI - PubMed
    1. Mandal G, Wyllie S, Singh N, Sundar S, Fairlamb AH, Chatterjee M. 2007. Increased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimony. Parasitology 134:1679–1687. doi:10.1017/S0031182007003150. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources